Total Payments
$175,402
2024 Payments
$17,200
Companies
38
Transactions
535
Medicare Patients
15,330
Medicare Billing
$1.9M
Payment Breakdown by Category
Other$157,200 (89.6%)
Food & Beverage$11,565 (6.6%)
Travel$6,481 (3.7%)
Education$139.44 (0.1%)
Consulting$16.61 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $157,200 | 69 | 89.6% |
| Food and Beverage | $11,565 | 441 | 6.6% |
| Travel and Lodging | $6,481 | 19 | 3.7% |
| Education | $139.44 | 5 | 0.1% |
| Consulting Fee | $16.61 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $146,165 | 216 | $0 (2024) |
| IRONWOOD PHARMACEUTICALS, INC | $12,194 | 42 | $0 (2024) |
| Allergan, Inc. | $11,235 | 44 | $0 (2020) |
| Janssen Pharmaceuticals, Inc | $782.54 | 7 | $0 (2022) |
| Ardelyx, Inc. | $702.86 | 30 | $0 (2024) |
| Gilead Sciences, Inc. | $436.19 | 21 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $423.70 | 17 | $0 (2024) |
| Phathom Pharmaceuticals, Inc. | $371.21 | 20 | $0 (2024) |
| Synergy Pharmaceuticals Inc | $366.18 | 16 | $0 (2018) |
| Braintree Laboratories, Inc. | $320.04 | 20 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $17,200 | 73 | ABBVIE INC. ($13,082) |
| 2023 | $28,234 | 96 | AbbVie Inc. ($23,493) |
| 2022 | $18,595 | 57 | ABBVIE INC. ($12,818) |
| 2021 | $22,479 | 63 | AbbVie Inc. ($21,722) |
| 2020 | $11,761 | 33 | AbbVie Inc. ($11,341) |
| 2019 | $28,502 | 75 | AbbVie, Inc. ($24,974) |
| 2018 | $26,940 | 84 | AbbVie, Inc. ($20,695) |
| 2017 | $21,690 | 54 | AbbVie, Inc. ($18,041) |
All Payment Transactions
535 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $25.69 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/11/2024 | IRONWOOD PHARMACEUTICALS, INC | Linzess (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,125.00 | General |
| Category: GI | ||||||
| 12/10/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $10.84 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/05/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $6.86 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/15/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $12.01 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/11/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $25.69 | General |
| Category: GI | ||||||
| 11/09/2024 | Celltrion USA Inc. | VEGZELMA (Biological) | Food and Beverage | In-kind items and services | $31.32 | General |
| Category: ONCOLOGY | ||||||
| 11/08/2024 | ABBVIE INC. | LINZESS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,125.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/08/2024 | ABBVIE INC. | LINZESS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,125.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/07/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $29.30 | General |
| Category: ENDOCRINOLOGY | ||||||
| 10/24/2024 | ABBVIE INC. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $113.39 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/22/2024 | ABBVIE INC. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $25.27 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/22/2024 | ABBVIE INC. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $23.33 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/21/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $33.96 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/15/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $34.95 | General |
| Category: LIVER DISEASE | ||||||
| 10/11/2024 | ABBVIE INC. | CREON (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,125.00 | General |
| Category: ENDOCRINOLOGY | ||||||
| 10/07/2024 | Celltrion USA Inc. | VEGZELMA (Biological) | Food and Beverage | In-kind items and services | $30.17 | General |
| Category: ONCOLOGY | ||||||
| 10/07/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $3.79 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/04/2024 | ABBVIE INC. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,125.00 | General |
| 10/02/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $8.73 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/30/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $25.75 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/26/2024 | IRONWOOD PHARMACEUTICALS, INC | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $22.54 | General |
| Category: GI | ||||||
| 09/19/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $114.10 | General |
| 09/18/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $7.52 | General |
| Category: ENDOCRINOLOGY | ||||||
| 09/16/2024 | AIMMUNE THERAPEUTICS, INC. | VOWST (Biological) | Food and Beverage | In-kind items and services | $25.92 | General |
| Category: GI | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 4,133 | 5,665 | $2.4M | $534,781 |
| 2022 | 15 | 4,117 | 5,334 | $2.2M | $506,334 |
| 2021 | 14 | 3,797 | 4,702 | $1.9M | $457,479 |
| 2020 | 16 | 3,283 | 4,026 | $1.7M | $381,439 |
Total Patients
15,330
Total Services
19,727
Medicare Billing
$1.9M
Procedure Codes
60
All Medicare Procedures & Services
60 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 367 | 1,540 | $231,000 | $102,219 | 44.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 800 | 1,034 | $155,100 | $78,105 | 50.4% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 788 | 788 | $236,400 | $69,164 | 29.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 392 | 441 | $110,250 | $47,961 | 43.5% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 226 | 228 | $342,000 | $47,743 | 14.0% |
| 45384 | Removal of polyps or growths of large bowel using a flexible endoscope with electrical cautery | Facility | 2023 | 237 | 237 | $284,400 | $44,457 | 15.6% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 581 | 586 | $527,400 | $43,340 | 8.2% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 236 | 237 | $260,500 | $36,349 | 14.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 241 | 247 | $70,395 | $26,985 | 38.3% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 99 | 107 | $13,375 | $8,202 | 61.3% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 27 | 79 | $15,800 | $7,876 | 49.8% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 44 | 44 | $57,200 | $7,340 | 12.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 42 | 43 | $11,610 | $6,248 | 53.8% |
| 43246 | Insertion of stomach tube using a flexible endoscope | Facility | 2023 | 36 | 36 | $43,200 | $5,878 | 13.6% |
| 43255 | Control of bleeding of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 17 | 18 | $24,300 | $2,914 | 12.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 821 | 1,089 | $156,000 | $82,241 | 52.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 925 | 925 | $277,500 | $81,577 | 29.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 324 | 1,170 | $169,950 | $70,677 | 41.6% |
| 45384 | Removal of polyps or growths of large bowel using a flexible endoscope with electrical cautery | Facility | 2022 | 240 | 240 | $288,000 | $46,356 | 16.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 359 | 401 | $97,750 | $46,132 | 47.2% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 191 | 191 | $286,500 | $41,482 | 14.5% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 510 | 516 | $464,400 | $40,010 | 8.6% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 211 | 211 | $232,100 | $33,062 | 14.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 195 | 196 | $55,860 | $22,006 | 39.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 195 | 206 | $25,320 | $15,823 | 62.5% |
About Dr. Frederick Boghossian, M.D
Dr. Frederick Boghossian, M.D is a Gastroenterology healthcare provider based in Glendale, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1841303849.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Frederick Boghossian, M.D has received a total of $175,402 in payments from pharmaceutical and medical device companies, with $17,200 received in 2024. These payments were reported across 535 transactions from 38 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($157,200).
As a Medicare-enrolled provider, Boghossian has provided services to 15,330 Medicare beneficiaries, totaling 19,727 services with total Medicare billing of $1.9M. Data is available for 4 years (2020–2023), covering 60 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Glendale, CA
- Active Since 08/16/2006
- Last Updated 01/17/2024
- Taxonomy Code 207RG0100X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1841303849
Products in Payments
- Creon (Drug) $38,204
- CREON (Drug) $36,390
- LINZESS (Drug) $35,605
- Linzess (Drug) $11,931
- VIBERZI (Drug) $5,632
- IBSRELA (Drug) $702.86
- ZEPOSIA (Drug) $516.70
- XARELTO (Drug) $426.92
- VOQUEZNA (Drug) $371.21
- Trulance (Drug) $366.18
- INVOKANA (Drug) $355.62
- STELARA (Biological) $204.27
- ZENPEP (Drug) $200.53
- SUPREP BOWEL PREP (Drug) $193.72
- DIFICID (Drug) $179.20
- TRULANCE (Drug) $179.04
- ENTYVIO (Biological) $176.78
- Amitiza (Drug) $154.28
- NEXLIZET (Drug) $123.02
- PANCREAZE (Drug) $115.85
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Glendale
Richard Manch, M.d, M.D
Gastroenterology — Payments: $630,233
Gastroenterology $630,233
Armine Sarkisian, M.d, M.D
Gastroenterology — Payments: $124,705
Gastroenterology $124,705
Mr. James Tabibian, M.d, M.D
Gastroenterology — Payments: $39,283
Gastroenterology $39,283
Dr. Vikram Singh, M.d, M.D
Gastroenterology — Payments: $34,147
Gastroenterology $34,147
Dr. Rimma Shaposhnikov, M.d, M.D
Gastroenterology — Payments: $23,780
Gastroenterology $23,780
Dr. Mehdi Khorsandi, M.d, M.D
Gastroenterology — Payments: $20,237
Gastroenterology $20,237